Focus: CathWorks is a public medical device company specializing in catheter guidance systems for cardiovascular interventions. The company focuses on AI-driven angiography analysis to improve coronary artery disease diagnosis and treatment.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
CathWorks offers exposure to innovative cardiology devices as a public company, but lack of current openings and transparent data limits immediate career opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CathWorks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CathWorks's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Medtronic Completes Acquisition of CathWorks to Strengthen Cardiovascular Diagnostics Portfolio - Digital Health News
Medtronic Completes Acquisition of CathWorks to Strengthen Cardiovascular Diagnostics Portfolio Digital Health News
Medtronic Completes $585M Acquisition of CathWorks - Medical Product Outsourcing
Medtronic Completes $585M Acquisition of CathWorks Medical Product Outsourcing
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease - PR Newswire
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease PR Newswire
Wire-free artery assessment tech joins Medtronic in $585M deal - Stock Titan
Wire-free artery assessment tech joins Medtronic in $585M deal Stock Titan
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment - PR Newswire
Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment PR Newswire
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles